Filter Results:
(448)
Show Results For
- All HBS Web
(637)
- People (2)
- News (57)
- Research (448)
- Events (2)
- Multimedia (9)
- Faculty Publications (392)
Show Results For
- All HBS Web
(637)
- People (2)
- News (57)
- Research (448)
- Events (2)
- Multimedia (9)
- Faculty Publications (392)
Sort by
- 12 Sep 2006
- First Look
First Look: September 12, 2006
alliance contracts, all of which concern early-stage research at small, biotechnology R&D companies. Staged investment is ubiquitous, but solutions to agency problems vary. The cycle of equity participation in alliances resembles what... View Details
Keywords: Sean Silverthorne
- 03 Feb 2009
- First Look
First Look: February 3, 2009
Contractibility and Contract Design in Strategic Alliances Authors: Josh Lerner and Ulrike Malmendier Publication: American Economic Review (forthcoming) Abstract We analyze how variations in contractibility affect the design of contracts in the context of View Details
Keywords: Martha Lagace
- 05 Dec 2013
- Op-Ed
Encourage Breakthrough Health Care by Competing on Products Rather Than Patents
Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics maker Myriad sought "the... View Details
- 26 Jul 2024
- Research & Ideas
Why Great Ideas Get Stuck in Universities
Entrepreneurs must overcome many barriers to get discoveries to market, but academic researchers face an additional one they might not realize: themselves. Academics tend to develop a myopic focus on the unique expertise they spend their lives developing, but that... View Details
- May 1999
- Teaching Note
Elliot Lebowitz TN
By: Paul A. Gompers
Teaching Note for (9-297-094). View Details
Keywords: Biotechnology Industry
- January 1998 (Revised September 2001)
- Case
Genset: 1989
By: Paul A. Gompers and Amy Burroughs
Discusses the start-up strategy at Genset, a French biotech firm. Pascal Brandys, a venture capitalist, and Marc Vasseur, a leading French scientist, must decide how to proceed. Future real options are central to the strategy. View Details
Gompers, Paul A., and Amy Burroughs. "Genset: 1989." Harvard Business School Case 298-070, January 1998. (Revised September 2001.)
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case. View Details
Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (B)." Harvard Business School Case 297-097, June 1997. (Revised September 1997.)
- March 2018 (Revised July 2018)
- Case
Greenlight Biosciences: In Search of Impact Investment
By: Michael Chu, Annelena Lobb and Joni Coughlin
Greenlight Biosciences, a biotech company, is in search of impact investment for its next round of financing. View Details
Keywords: Impact Investment; Investment; Environmental Sustainability; Financing and Loans; Biotechnology Industry
Chu, Michael, Annelena Lobb, and Joni Coughlin. "GreenLight Biosciences: In Search of Impact Investment." Harvard Business School Case 318-072, March 2018. (Revised July 2018.)
- November 2016
- Case
Anthony Starks at InSiL Therapeutics (A)
By: Gary Pisano and Vicki Sato
When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a few months in, Wayne and Starks begin to clash over crucial forward-looking decisions about the... View Details
Keywords: Biotech; Silicon; Managing Innovation; Management Challenges; Managing People; Managing Organization; R＆D; R＆D Project Management; Platform; Venture Capital; Drug Discovery; management; Biotechnology Industry; California
Pisano, Gary, and Vicki Sato. "Anthony Starks at InSiL Therapeutics (A)." Harvard Business School Case 617-029, November 2016.
- January 2012 (Revised August 2012)
- Case
Dirigo International
By: Christopher M. Gordon and Chad M. Carr
Dirigo International is proposing a major expansion of their life sciences research and manufacturing facilities in the heart of a major city and middle to lower income residential neighborhood. The company and city government are seeking a development solution in the... View Details
Keywords: Production; Property; Expansion; Governing Rules, Regulations, and Reforms; Business and Government Relations; Research and Development; Outcome or Result; Biotechnology Industry
Gordon, Christopher M., and Chad M. Carr. "Dirigo International." Harvard Business School Case 212-056, January 2012. (Revised August 2012.)
- August 2010 (Revised August 2012)
- Supplement
Generation Health: A Pioneer in Genetics Benefit Management (B)
By: Robert F. Higgins
Higgins, Robert F. "Generation Health: A Pioneer in Genetics Benefit Management (B)." Harvard Business School Supplement 811-005, August 2010. (Revised August 2012.)
- January 2010 (Revised August 2011)
- Case
Ganeden Biotech, Inc.
By: Robert C. Pozen, Dale Alan Winger and Matthew Kenneth Ahlers
The CEO of Ganeden Biotech, a small firm with several viable probiotic products but limited resources, must decide what markets to invest in and what intellectual property strategies will best serve its immediate and longer-term business interests. View Details
Keywords: Entrepreneurship; Investment; Intellectual Property; Market Entry and Exit; Business Strategy; Biotechnology Industry
Pozen, Robert C., Dale Alan Winger, and Matthew Kenneth Ahlers. "Ganeden Biotech, Inc." Harvard Business School Case 310-073, January 2010. (Revised August 2011.)
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- July 2009
- Teaching Note
Targanta Therapeutics: Hitting a Moving Target (TN)
By: Arthur A. Daemmrich
Teaching Note for [709002]. View Details
- May 2004
- Teaching Note
Monsanto: Technology Cooperation and Small Holder Farmer Projects (TN)
By: James E. Austin and Diana Barrett
Teaching Note to (9-302-068). View Details
Keywords: Biotechnology Industry
- November 2001 (Revised December 2002)
- Case
Tracking Stocks at Genzyme (A)
Genzyme, a tracking stock pioneer, has used its innovative capital structure as a way to frame and grow its R&D-intensive business. Facing the question of how best to integrate a new acquisition into its tracking stock structure, Genzyme's top management is forced to... View Details
Keywords: Integration; Value Creation; Motivation and Incentives; Conflict of Interests; Stocks; Capital Structure; Research and Development; Corporate Governance; Biotechnology Industry
Salter, Malcolm S. "Tracking Stocks at Genzyme (A)." Harvard Business School Case 902-023, November 2001. (Revised December 2002.)
- October 2001
- Case
TIGR and ILRI: Solving Problems with Genomics
By: Ray A. Goldberg and James M Beagle
Discusses nonprofit institutional leadership applying advances in genetic science to solve health and animal problems in industrial countries and the developing world. View Details
- October 2001 (Revised June 2002)
- Case
Centagenetix (A): Building a Business Model for Genetic Longevity
Describes a start-up company seeking to exploit population genetic data from long-lived, healthy people. The company must address legal, financial, ethical, and personal issues among its team to launch the company. View Details
Chesbrough, Henry W., and Frank Angella. "Centagenetix (A): Building a Business Model for Genetic Longevity." Harvard Business School Case 602-087, October 2001. (Revised June 2002.)
- April 2001 (Revised January 2003)
- Case
Robert Shapiro and Monsanto
Traces Monsanto's efforts to become a global biotech powerhouse under Shapiro's leadership. Examines how his crusade to save the world through genetic modification foundered. View Details
Keywords: Genetics; Supply Chain Management; Alliances; Global Strategy; Cross-Cultural and Cross-Border Issues; Biotechnology Industry
Watkins, Michael D., and Ann Leamon. "Robert Shapiro and Monsanto." Harvard Business School Case 801-426, April 2001. (Revised January 2003.)
- December 2000
- Case
Paradigm Genetics: The Industrialization of Genomics
By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock
Goldberg, Ray A., Carin-Isabel Knoop, and Laure Mougeot Stroock. "Paradigm Genetics: The Industrialization of Genomics." Harvard Business School Case 901-011, December 2000.